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Bisphosphonates are agents used to treat or prevent os-
teoporosis and treat malignant bone lesion. These agents
have been increasingly recommended for use in patients
with osteoporosis, Paget’s disease of bone, osteolytic bone
metastases, and so on.
1-4 Also, these agents reduce skele-
tal complications such as pain, pathologic bony fracture,
and size of osteolytic lesion.
1-3 Oral bisphosphonates such
as alendronate (Fosamax) and risedronate (Actonel) are
used for the treatment of postmenopausal osteoporosis.
These medications are usually prescribed once a week
(aledronate 70mg, risedronate 35mg).
1
Despite the benefits related to the use of these medica-
tions, osteonecrosis of the jaws is a significant complica-
tion in a subset of patients receiving these drugs.
1,2,5,6 It
appears that the pathogenesis of this process is most con-
sistent with a defect in the jaw bone physiologic remodel-
ing or wound healing. The negative impact of bisphospho-
nate is the inhibition of osteoclast function.
1-3,5 Once depo-
sited on the surface of bone, bisphosphonates are internal-
ized by osteoclast, causing disruption of osteoclast-medi-
ated bone turnover and resorption.
2-4
This complication usually presents after dento-alveolar
trauma, elective dental surgery or tooth extraction.
5-8 How-
ever, a subset of edentulous and dentate patients have de-
veloped necrotic bone spontaneously.
2 There is an increas-
ing concern that the oral bisphosphonates are implicated
in osteonecrosis of the jaws.
8
Recently there were patients showing the features of bis-
phosphonate related osteonecrosis of the jaws (BRONJ).
This report demonstrates 2 cases of BRONJ examined
using plain radiography and computed tomography(CT).
Case Report
Case 1
A 74-year-old woman had a complaint of bony exposure
on the left posterior maxilla after spontaneous loss of the
left maxillary first and second molars 3 months ago. She
had been taking oral risedronate (Actonel), a kind of bis-
phosphonates, 35 mg once weekly for 4 years because of
osteoporosis. The intraoral examination revealed the bony
exposure on the left maxillary alveolar region, pus dis-
charge, and bleeding on the same site as well as sequestrum
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The patient took a panoramic radiograph and CT. On
the panoramic radiograph, a large osseous crater and cor-
tical bone destruction were found on the left maxillary ede-
ntulous area (Fig. 2). CT images demonstrated cortical
bone destruction on the left maxillary edentulous area and
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Fig. 1. Intraoral examination reveals alveolar bone exposure(A) and detached sequestrum(B) on left maxillary area of case 1.
AB
Fig. 2. Panoramic radiograph shows
a large osseous crater on left maxil-
lary edentulous area.
Fig. 3. A. Axial CT image reveals
cortical bone destruction, sclerotic
change of adjacent trabecular bone.
B. Axial CT image reveals numer-
ous bony fragments that is consider-
ed as sequestrum.
ABmaxillary sinus wall. Adjacent trabecular bone showed
sclerotic change. The lesion extended to the maxillary
sinus floor and mucositis were observed on the sinus floor.
Also there were scattered sequestra on the left maxilla and
sinus floor(Fig. 3). 
The patient was diagnosed with BRONJ from the clinical
and radiological examinations. Treatment began with the
cessation of bisphosphonates therapy and removal of the left
maxillary first premolar. Saucerization and decortication
were performed on that area with sequestrectomy(Fig. 4). 
Biopsy from the lesion of bone demonstrated sequestrum
infiltrated with chronic inflammatory cells. There was not
vivid osteocyte in the lacunae(Fig. 5). Through the histo-
pathologic feature, this case was confirmed as BRONJ.
During 6 months follow-up period, there was no sign of
recurrence(Fig. 6).
Case 2
A 72-year-old woman had a chief complaint of swelling
on the left maxillary canine area after extraction of the left
maxillary canine 2 months ago. She had been taking oral
risedronate (Actonel), a kind of bisphosphonates, 35 mg
once weekly for 3 years and 5 months because of osteo-
porosis. The intraoral examination showed a necrotic bone
exposure on the left maxillary edentulous area with a swel-
ling and pus discharge through a fistula.
The patient took the intraoral and panoramic radiographs,
and CT. Plain radiological examination showed a sequest-
rum of bony fragment with trabeculation at the socket area
(Fig. 7). CT images demonstrated the separated lamina
dura from the extraction socket of the canine and mild
mucositis on the left maxillary sinus (Fig. 8). The patient
was diagnosed with osteomyelitis from the clinical and
radiological examinations. The treatment was performed
with saucerization, fistulorraphy, and sequestrectomy. 
The patient revisited 1 year and 6 months later. The chief
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Fig. 4. Saucerization and decortication are performed on that area
with sequestrectomy.
Fig. 5. Photomicrograph of specimen of biopsy shows infiltration
of chronic inflammatory cell and no vivid osteocyte in the lacunae
(H&E stain, ×200).
Fig. 6. Panoramic radiograph shows
bone remodeling on the 6 months
follow-up period in case 1. There is
no sign of recurrence on left maxil-
lary area.complaint was bony exposure on the right mandibular eden-
tulous area with pus discharge(Fig. 9). Plain radiographic
examination showed the decrease in bone density on the
right mandibular alveolar process, resorptive area with
irregular shape, and sequestrum on the crestal area(Fig. 10).
The patient was diagnosed with BRONJ from the clinical
and radiological examinations. Treatment began with the
cessation of bisphosphonates therapy. And then, sauceriza-
tion and decortication were performed on that area with
sequestrectomy. Biopsy from the bony lesion demonstrated
sequestrum infiltrated with chronic inflammatory cell as
well as bacterial flora (Fig. 11). Histopathologic findings
confirmed the diagnosis of BRONJ. During 3 months
follow-up period, there was no recurrence sign.
Discussion
Bisphosphonates inhibit osteoclast-mediated bone turn-
over and endothelial cell function. Cells treated with bis-
phosphonates demonstrate decreased proliferation, incre-
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Fig. 8. A. Axial CT image reveals
separated lamina dura on socket of
left maxillary canine. B. Axial CT
image shows mild buccal soft tissue
swelling.
AB
Fig. 7. A. Intraoral radiograph of case 2 reveals bony fragment with trabeculation on socket of left maxillary canine. B. Panoramic radio-
graph shows separated lamina dura on socket of left maxillary canine.
AB
Fig. 9. Intraoral examination of case 2 reveals recurrence sign of
alveolar bone exposure and pus discharge on right mandibular
edentulous area.ased rate of apoptosis, and a decrease in capillary-tube for-
mation.
1,4 Bisphosphonates also demonstrate antiangioge-
nic properties owing to their ability to significantly decre-
ase circulating levels of vascular endothelial growth factor
(VEGF).
1,8
BRONJ was first reported in 2003, recognized a few
years after bisphosphonates approval for use.
9 There was
a growing number of BRONJ in patients receiving oral bis-
phosphonates therapy. Ortega et al reported that the inci-
dence of BRONJ varied from 0.15% to 12% of patients
receiving bisphosphonates for treatment of osteoporosis.
10
There is an increasing concern that oral bisphosphonates
are implicated in osteonecrosis of the jaws, albeit less com-
monly than that observed with the more potent intravenous-
ly administered bisphosphonates. Recent retrospective cli-
nical studies have identified several potential risk factors
associated with the development of BRONJ. These include
a history of dento-alveolar trauma, duration of bisphospho-
nates exposure, and the type of bisphosphonates.
3,7,9-12 In
the majority of BRONJ cases reported to date, recent dento-
alveolar trauma was the most prevalent and consistent risk
factor.
3
The lesion related with BRONJ is most frequently symp-
tomatic when surrounding tissues become inflamed or
there is a clinical evidence of infection. Signs and symp-
toms include pain, tooth mobility, mucosal swelling, ery-
thema, and ulceration.
2-8 Some patients may also present
with complaints of altered sensation in the affected area.
2
These cases showed the clinical features such as pain, bone
exposure, pus discharge, bleeding, and swelling. The pati-
ents had been taking oral risedronate(Actonel), a kind of
bisphosphonates 35mg, once weekly for treatment of osteo-
porosis for 4 years and 3 years 5 months, respectively. In
both cases, there were loss of teeth that could be regarded
as the causative factor of dento-alveolar trauma and sub-
sequent osteonecrosis of the jaws.
Radiographic changes are not evident until there is sig-
nificant bone involvement. Therefore, panoramic and peri-
apical radiographs may not reveal significant changes in
the early stages of osteonecrosis.
1-3 Early or late radiogra-
phic changes may mimic classic periapical pathology or
osteomyelitis. In the cases presented, plain radiographs
and CT images were taken, which showed signs of bone
destruction with sequestrum and mucositis on the adjacent
maxillary sinus. These features were not differed from clas-
sic osteomyelitis.
Magopoulos et al
3 reported that cessation of bisphos-
phonates therapy combined with surgical debriment and
long term antibiotic therapy was the treatment of choice
in BRONJ patients. In case 1, the patient was treated with




decreased bone density and seques-
trum on right mandibular area.
Fig. 11. Photomicrograph of sequestrum shows heavy infiltration
of chronic inflammatory cell and bacterial flora(H&E stain, ×200).problematic area with the cessation of bisphosphonates
therapy. During the follow-up period of 6 months, there
was no recurrence sign. In case 2, the patient was treated
with saucerization, fistulorraphy, and sequestrectomy with-
out cessation of medication. However, there was recurrence
of osteonecrosis on the mandible after 1 year 6 months.
Treatment was performed again on the recurrent area. Sau-
cerization, decortications, and sequestrectomy were per-
formed with the cessation of bisphosphonates therapy.
During the follow-up period of 3 months, there was no sign
of recurrence after the retreatment. 
It is critical that the dentist should be aware of this sig-
nificant complication which can occur spontaneously or
after any dento-alveolar procedure in the population receiv-
ing bisphosphonates. Because the oral examination and
review of the patient’s medical history are currently the
most effective and sensitive means of detecting BRONJ,
dental professionals are in a unique position to identify and
diagnose this disease process early in its course.
This report serves to alert dentists about the potential
complication of bone necrosis in patients receiving bis-
phosphonates therapy. For the treatment of BRONJ, den-
tists need to consider ceasing the use of bisphosphonates.
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